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Abstract
Polymeric nanoparticles (NPs) are recognized as potential delivery vehicles for vaccines. PLGA is a 
biocompatible polymer synonymous with polymeric NPs, which can be coated with other polymers 
such as chitosan that has intrinsic adjuvant properties as well as mucoadhesive properties. Numerous 
modifications and variations exist for PLGA and chitosan, which can influence the NP characteristics 
and the resulting immunogenicity. The current study investigated variations for making chitosan 
coated PLGA NPs incorporating recombinant pneumococcal surface protein A from family 2, clade 4 
(PspA4Pro) antigen as a vaccine targeting the vast majority of pneumococcal strains and determine 
the effect of the polymers on particle size, surface charge, and surface marker upregulation on a 
dendritic cell (DC) line in vitro. PLGA variations tested with the ester-terminal group had the greatest 
detriment for prospective vaccine use, due to the lowest PspA4Pro adsorption and induction of CD40 
and CD86 cell surface markers on DCs. The negatively charged chitosans exhibited the lowest surface 
marker expressions, similar to the uncoated NP, supporting the commonly accepted notion that 
positive surface charge augments immunogenic effects of the NPs. However, the study indicated that 
NPs made from PLGA with an acid terminated group, and chitosan HCl salt, exhibit particle 
characteristics, antigen adsorption efficiency and immunogenicity, which could be most suitable as a 
vaccine formulation.
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1. Introduction
The emergence of novel pathogens and rise in antimicrobial resistance has been a key driver of vaccine 
development in recent times. Among this development, subunit vaccines, using recombinant proteins 
based on a specific portion of the pathogen, have been gaining interest due to the precision of the 
resulting immune response and reduced potential for adverse effects [1]. Although recombinant 
protein antigens exhibit greater safety and precision, one of the main limitations of such antigens is 
the weak intrinsic immunogenicity, which necessitates additional forms of immunostimulation to 
induce a sufficient immune response that leads to protection. 
The immunogenicity of nanoparticles (NPs) can arise from different avenues, including targeting, 
uptake and proficient delivery of antigen and adjuvant [2-4]. Poly(lactic-co-glycolic acid) (PLGA) is a 
particularly popular biocompatible copolymer used to make NPs, and it is already used in various FDA 
approved therapeutics. The PLGA polymer is available in numerous forms based on the molecular 
weight, terminal end group and ratio between the lactic and glycolic acid monomers. These 
parameters may influence NP characteristics and thus interaction with the immune cells or the 
environment. Administration of an antigen with the NPs have been shown to result in induction of 
adaptive immune responses and subsequent increases in antigen-specific antibody levels, which leads 
to protective immunity [4]. 
Adsorption of the antigen onto the NP surface, through electrostatic and ionic interaction, is a simple 
approach for the incorporation of the antigen to the NP [5]. The presence of the antigen at the particle 
surface also mimics pathogens which have the antigen in the cell wall, such as the pneumococcal 
surface protein A (PspA) in Streptococcus pneumoniae. This antigen is of interest as it potentially offers 
protection against a wide range of pneumococcal strains, compared to the currently available 
conjugate vaccine [6]. Furthermore, adsorption avoids potential degradation and denaturation of the 
antigen structure during preparation of the NPs, which generally involves contact with organic 
solvents and high energy homogenisation [7]. 
Incorporation of chitosan on the surface of polymeric NPs has been shown to improve immunogenicity 
and delivery of encapsulated material at mucosal sites [8]. The interest for use in vaccine applications 
is commonly attributed to several mechanisms: the immunogenicity from the positive charge of the 
amine group, increase in residence time and antigen presentation through mucoadhesion, and the 
reversible opening of tight gap junctions between epithelial cells [9]. Another mechanism occurs 
through recognition by the Toll-Like Receptor (TLR) pathway and the induction of innate immune 
responses, generating type I interferons that mediate maturation of dendritic cells (DCs). In addition, 
chitosan can induce mitochondrial stress and the subsequent increase in reactive oxygen species (ROS) 
production [9, 10]. This results in the opening of mitochondrial permeability transition pores and 
release of mitochondrial DNA, which is likely recognized as a danger-associated molecular pattern 
(DAMP) that serves as a trigger for cyclic GMP–AMP (cGAS) activation. Furthermore, chitosan has the 
potential to be modified, with studies on various forms of chitosan claiming improvements in solubility, 
mucoadhesiveness, and penetration enhancement that can contribute to the delivery and 
immunogenicity of vaccine formulations [9, 11]. 
DCs are arguably the most crucial of potent antigen presenting cells (APCs), which exhibit highly 
phagocytic capacity and can initiate adaptive immune responses leading to memory and protection. 
Substantial evidence indicates that interactions depend on the physicochemical properties, especially 
the surface chemistry of NPs, which influences the recognition and uptake [12, 13]. Particle size also 
influences uptake by DCs, with a size of 300 nm exhibiting high uptake efficiency; although there are 
still ambiguities in how size relates to immunogenicity [13, 14]. The stimulation of DCs by NPs 
ultimately leads to metabolic changes and upregulation of costimulatory molecules, such as such as 
CD80, CD86, and CD40, and production of cytokines. All which serve to stimulate immature T cells 
during antigen presentation [13]. During the development of an adaptive immune response, the 
function of DCs is immensely influential in initiating differentiation for tolerance, memory, and T-
helper 1 (Th1), Th2 and Th17 responses.
The aforementioned properties of NPs such as those arising from the use of different PLGAs and 
coating with chitosans of various properties, are highly important for driving the desired immune 
response outcome. By understanding how such differences in the polymers and how it affects the 
subsequent particle properties and the immunogenicity on the DCs, the optimal combination could 
be chosen for the desired application. This study investigated the effect of different PLGA polymers 
and chitosans on the resulting characteristics of chitosan coated PLGA NPs, and the subsequent 
immunogenicity of the NPs on DCs through upregulation of cell surface activation markers in an in 
vitro JAWSII cell model.
2. Materials and methods
2.1. Materials
PLGA (Lactide:glycolide (50:50), acid terminated, average Mw 7-17 kDa), (Lactide:glycolide (50:50), 
ester terminated, average Mw 7-17 kDa), (Lactide:glycolide (50:50), acid terminated, average Mw 24-
38 kDa) and (Lactide:glycolide (75:25), acid terminated, average Mw 4-15 kDa) polyvinyl alcohol (PVA), 
were obtained from Sigma, UK. Chitosan hydrochloride (HCl), carboxymethyl chitosan (CMC), chitosan 
oligomer, chitosan glutamate, were obtained from Heppe Medical Chitosan GmbH, Germany. The 
dendritic cell line, JAWS II (CRL-11904TM), was purchased from American type culture collection 
(ATCC). Alpha minimum essential medium (α-MEM), fetal calf serum (FCS), trypLE, sodium glutamate, 
and granulocyte macrophage colony-stimulating factor (GM-CSF) were purchased from Life 
technologies, UK. Purified water from a Millipore Purification System (Billerica, MA, USA) was used 
throughout the study. 
2.2. Preparation of NPs
PLGA NPs were prepared using the solvent evaporation method. Briefly, 200 mg of the PLGA polymer 
(Table 1) was dissolved in 2 mL dichloromethane (DCM), added dropwise to 3 mL of 10 % w/v PVA 
while ultrasonicating (Q125 Ultrasonic Homogenizer, Qsonica, USA) for 2 min at 65% amplitude on 
ice. The resulting O/W emulsion was added dropwise to 4 mL of 0.5 % PVA and stirred for 3 h to allow 
the DCM to evaporate. The resulting suspension was centrifuged at 80,000 ×g in a Beckman Coulter 
type 70.1 rotor for 30 min, the supernatant was discarded, and the pellet was resuspended in 3 mL of 
water, with 30 sec agitation in a bath sonicator (Sonorex, Bandelin, Germany). 
2.3. Coating with chitosan
The PLGA NPs were coated with the chitosans (Table 2) through electrostatic interactions. The 
chitosans were first dissolved in 1% acetic acid and added to the second aqueous phase during PLGA 
NP preparation, at a final concentration of 1 mg/mL or as indicated in the experiment. The NPs were 
processed in the same manner as without chitosan.
2.4. Surface adsorption with PspA4Pro and quantification using HPLC
To surface adsorb NP +/- chitosan with PspA4Pro, 1 mL of 1 mg/mL PspA4Pro was added to the 3 mL 
of 25 mg NP suspension (produced in 2.2 and 2.3) and mixed with a magnetic stirrer at room 
temperature for 1 h. The NP suspension was ultracentrifuged at 80,000 ×g in a Beckman Coulter type 
70.1 rotor. The adsorption of PspA4Pro on the NPs was quantified using a previously developed high 
performance liquid chromatography (HPLC) method in our group [15]. The adsorption was calculated 
by the difference between the initial amount of PspA4Pro and the amount detected in the supernatant
2.5. Particle size and zeta potential characterisation
The size of particles and polydispersity index (PDI) was measured at 20°C, in deionised water, at a 
concentration of 0.1 mg/mL, using dynamic light scattering (Zetasizer Nano, Malvern Instruments Ltd, 
Malvern, Worcestershire, UK). The zeta potential was measured by electrophoretic mobility using a 
capillary cell in the same machine. The hydrodynamic diameter measurements are reported as 
intensity 
2.6. Quantification of coated chitosan
The quantity of chitosan adsorbed to the surface of NPs was determined by the fluorescamine assay. 
Chitosan coated NPs were ultracentrifuged at 80,000 ×g and the supernatant was obtained. A 50 µL 
aliquot of fluorescamine in DMSO (2 % w/v) was added to 20 µL of the supernatant sample in wells of 
a 96-well plate. The reaction continued for 3 h in the dark and the fluorescence in the wells were 
measured at 390 nm excitation and 515 nm emission, using a microplate reader (CLARIOstar® BMG 
Labtech, Germany). A standard curve was prepared for each type of chitosan by spiking blank 
supernatant with predefined quantities of the chitosans. The adsorption was calculated by the 
difference between the initial amount of chitosan and the amount detected in the supernatant
2.7. Evaluation of NP immunogenicity and toxicity in JAWSII cells
JAWSII cells were seeded at a concentration of 50,000 cells/mL in 24 well plates, with complete 
medium (α-MEM containing ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium 
pyruvate supplemented with 20% FCS, 5 ng/ml murine GM-CSF and 1% antibiotic/antimycotic solution. 
The cells were incubated at 37 °C, 5% CO2 for 48 h, the NP formulations were added to the wells at a 
final concentration of 0.1 mg/mL for PLGA-only experiments (Section 3.2) and 0.05 mg/mL for chitosan 
coated NP experiments (Sections 3.4-3.7), and the cells were incubated for a further 24 h. The plate 
was centrifuged at 300 ×g for 5 min, the supernatant removed, 100 µL of TrypLE added to each well, 
and incubated for 5 min. The cells were removed from the wells with 1 mL of PBS, transferred to 
microtubes, centrifuging at 300 ×g for 5 min then removing the supernatant. The cells were washed 
by resuspending the cells in PBS and repeating the centrifugation. The cells were stained with anti-
mouse CD40-FITC and CD86-PE, washed and resuspended in 7AAD (1:500). The cells were analysed 
using a BD Accuri™ C6 flow cytometer, and gated according to the signals (Figure S1). The toxicity was 
determined by gating for the 7AAD negative cell population and expressed as the live proportion 
within the total population of cells. The immunogenicity was determined by the CD40 and CD86 
surface expressions, which were measured as the mean fluorescence intensity (MFI).
2.8. Statistical analysis
Results are expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) with 
Tukey’s pairwise comparison or unpaired t-tests were used to compare groups using Prism 6 
(GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was determined as p<0.05.
3. Results
3.1. Characterisation of PLGA NPs
NPs prepared from PLGA with differences in the glycolic acid:lactic acid ratio (50:50 and 72:25), 
polymer size (7-17 kDa and 24-38 kDa), and polymer terminal group (ester and carboxylic acid), 
produced particles of similar sizes at ~150 nm and PDI <0.2 and zeta potential of -14 mV (Figure 1A-
C). There were no statistically significant differences between the characteristics resulting from 
different PLGA polymers. After surface adsorption of PspA4Pro, the NP size did not significantly 
increase. This is despite the high degree of PspA4Pro adsorption to the particle surfaces at >90% for 
REF, HMW and LAC (Figure 1D). EST was alone in exhibiting significantly lower PspA4Pro adsorption 
of 16 % (Figure 1D). The PDI increased after protein surface adsorption but the NPs remained relatively 
homogenous with all PDI values under 0.2. The zeta potentials for all polymer particles were all 
negative in the range of -14 to -30 mV before coating with PspA4Pro. After coating, the zeta potentials 
were more negatively charged, with EST gaining additional negative charge of ~10 mV.
3.2. Immunogenicity of PLGA NPs
The degree of immunogenicity of the PLGA NPs were evaluated by incubating the formulations with 
the immortalised DC cells (JAWSII) and measuring surface marker expression of CD40 and CD86, 
indicative of DC activation. To initially determine the optimal NP concentration and incubation time 
for measuring the response, REF NPs at concentrations from 0.1 to 1000 µg/mL, were incubated with 
JAWSII cells for 24 h (Figure S2A&B). The REF NPs at 100 µg/mL were also incubated for a 48 h time 
course (2, 4, 16, 24, 48 h) (Figure S2C&D). The NP stimulated the CD40 and CD86 JAWSII expression in 
a concentration dependent manner, with 100 µg/mL inducing significantly higher expression 
compared to culture media alone. Over the 48 h time course, the NPs exhibited positive relationship, 
showing increased surface marker expression with increasing incubation time. 
The LAC exhibited significantly lower degree of cell viability compared to the other PLGAs, although 
this was still above 85% viability (Figure 2A). With the exception of the EST, the NPs with and without 
the adsorbed PspA4Pro, were shown to induce the upregulation of the surface markers (Figure 2B&C). 
As the particle sizes were similar between the different polymers, the relatively lower magnitude of 
negative surface charge and greater hydrophobicity of the ester PLGA NP appears to have significant 
influence on the NP to DC interaction. 
The toxicity and immunogenicity were unaffected by the presence of PspA4Pro, indicating the antigen 
itself has no role in the upregulation of surface markers in DCs in this assay. This was supported by the 
lack of CD40 and CD86 upregulation by PspA4Pro alone (Figure S3). The LAC was the most significant 
contributor to immunogenicity (Figure 2B&C), likely due to the presence of a negative charge, which 
is absent in the EST. The HMW (24-38 kDa) also induced lower surface marker upregulation relative to 
the REF (7-17 kDa). 
3.3. Coating with chitosan
Chitosans of varying molecular configurations (Table 2) were investigated for particle characteristics 
and immunogenicity, using REF as the PLGA NP component. After coating NPs with different chitosans, 
the resulting NP exhibited little changes in particle size, apart from CMC, which exhibited an average 
diameter of over 200 nm compared to the uncoated NP with 180 nm (Figure 3A). The PDI values were 
mostly under 0.3, with the exception of the PspA4Pro adsorbed Glycol chitosan coated NP (Figure 3B). 
The zeta potential of the various chitosan coated NPs varied from +30 mV of the glycol chitosan to -
30 mV of the CMC (Figure 3C). These differences reflect the differences in the ionisation states of the 
polymers. 
The addition of PspA4Pro generally increased particle sizes, with the glycol chitosan exhibiting an 
increase that resulted in the largest particles outright at 600 nm. This increase in size was not entirely 
correlated to the amount of PspA4Pro adsorption, as HCl, glutamate and glycol chitosans exhibited 
near 100% PspA4Pro adsorption, but only the glycol resulted in such significant increase (Figure 3A). 
Furthermore, the zeta potentials decreased to be closer to neutral for HCl, LMW, and TMC chitosans, 
but increased for glutamate and glycol chitosans (Figure 3C). 
The PspA4Pro adsorption efficiency also varied greatly with different chitosans. PspA4Pro adsorption 
and zeta potential appeared to exhibit some correlation, as the negatively charged CMC and oligomer 
chitosan coated NPs exhibited under 10% adsorption efficiency, whereas the positively charged HCl, 
glutamate and glycol chitosan coated NPs exhibited over 90% efficiency (Figure 3E). 
Measurement of chitosan adsorption revealed that the degree of adsorption varied between each 
chitosan (Figure 3D), when a constant chitosan concentration was used during the preparation process 
(1 mg/mL). The HCl, TMC, CMC and glycol chitosans exhibited the highest adsorption onto particles at 
55-70 %, while the LMW, oligomer and glutamate chitosans were below 45 %. The chitosan adsorption 
was also not correlated to surface charge as CMC, which has negative zeta potential, exhibited a high 
degree of chitosan surface adsorption. 
3.4. Chitosan immunogenicity related to adsorption efficiency
Incubation of the chitosan coated NPs with JAWSII cells resulted in various degrees of CD40 and CD86 
expression (Figure 3F&G), with the chitosan HCl exhibiting significant increases in expression 
compared to non-chitosan coated NPs. There were minimal differences between CMC, oligomer 
chitosans compared to uncoated NP for CD40. The high adsorbance of CMC, despite the low CD40 and 
CD86 upregulation, indicates that CMC has low intrinsic immunogenicity. This effect by CMC and 
oligomer could indicate that the zeta potential could have the greatest influence on CD40 and CD86 
upregulation in this cell model. The effects of the chitosans did not appear to be correlated solely to 
any other specific NP characteristic. However, the zeta potential in the positive range did not correlate 
to the degree of surface marker upregulation. This could be observed for glycol chitosan exhibiting a 
high positive zeta potential, but inducing less upregulation compared to HCl, which had a lower zeta 
potential. 
3.5. Effect of chitosan preparatory concentration
As the chitosan loading differed for each chitosan, the correlation between preparatory chitosan 
concentration, the resulting chitosan adsorption efficiency, and the degree of DC activation with 
equivalent amounts of chitosan, needed to be elucidated. The relationship between the chitosan 
concentrations in the emulsion during NP preparation and the final adsorption onto the NPs was 
determined by preparing NPs coated with the positively charged chitosans at different concentrations 
(0.2, 0.5, 1.0 and 2.0 mg/mL). 
The change in particle size, resulting from the coating, exhibited differing patterns between different 
chitosans (Figure 4). The size difference between the lowest and highest tested preparatory 
concentrations (0.2 and 2 mg/mL) ranged from no change for HCl and TMC, to an increase of ~120 nm 
for LMW and Glycol. The PDI was similar between chitosan preparatory concentrations, indicating 
consistent increases in homogenous particle size. The zeta potential exhibited a concentration 
dependent pattern, with the largest change occurring between the 0.2 and 0.5 mg/mL preparatory 
concentrations. HCl, TMC and Glycol possess zeta potentials close to neutral at 0.2 mg/mL, indicating 
that the PLGA still has a large influence on the charge characteristics of the resulting NPs. 
The loading capacity profile is also unique between different chitosans. HCl exhibits increasing loading 
capacity with increasing preparatory concentration, whereas glycol chitosan had very little change 
above the lowest concentration. This is further shown in in the adsorption efficiency (Figure 4D) which 
shows HCl with a relatively constant adsorption efficiency 50-60%, whereas the glycol exhibits a 
decrease in adsorption efficiency with increasing preparatory concentration. When comparing the 
loading capacity to the particle characteristics (Figure 4E), the results for LMW and Glycol chitosan are 
contrasting. The size, zeta potential and loading capacity appear to be correlated for the LMW, 
whereas the plateau observed for the Glycol appears to correlate with the zeta potential, but not with 
the continued increase in particle size (Figure 4A).Overall, the chitosan HCl appeared to have the 
highest adsorption efficiency and thus the highest amount of chitosan coating at any starting chitosan 
concentration. A notable anomaly for the total adsorbed chitosan was the glycol chitosan, which 
exhibited a plateau in the adsorbed amount (Figure 4E) even when the preparation concentration 
increased. 
The varying amounts of adsorbed chitosan were tested in the JAWSII cells, which indicated a mixed 
response between the total amount of adsorbed chitosan and the expression of surface markers 
(Figures 5). LMW chitosan was the only chitosan, with which the highest chitosan concentration and 
chitosan loading capacity, resulted in the highest surface marker expression. The correlation could 
also be applied to glycol, which had plateaus after 0.2 mg/mL for both loading capacity and surface 
marker upregulation. The other chitosans of HCl and glutamate, exhibited some degree of 
concentration dependent surface marker upregulation, but the response did not follow chitosan 
concentration. This was especially apparent for HCl, which exhibited a plateau in both CD40 and CD86 
expressions, despite the increase in the chitosan loading capacity. This could be an indication that 
there is an upper limit of DC stimulation for chitosan HCl, which is limited through surface charge, as 
the particles with zeta potential above +20 mV exhibited similar CD40 and CD86 upregulation. 
3.6. NP characteristics with equal chitosan loading capacity
As the chitosan loading capacity was shown to be influential in particle characteristics and 
immunogenicity, chitosan coated NPs with similar loading capacities were prepared in order to 
compare the effects of the chitosans at comparable loading. The adsorbed amount, corresponding to 
5% loading capacity, was chosen and prepared using the appropriate chitosan concentration during 
preparation for each chitosan. The resulting particles exhibited predictable particle properties when 
produced with equal chitosan loading capacities. As seen in Figure 6A, the LMW, Glutamate and Glycol 
coatings resulted in the largest increases in particle size, whereas the HCl remained similar to the 
uncoated chitosan. The zeta potential ranged from +20 mV to +40 mV (Figure 6C), with LMW having 
the highest compared to the rest.
3.7. Immunogenicity with equal chitosan loading capacity
The chitosan HCl consistently exhibited the highest expression of both CD40 and CD86 compared to 
the uncoated NP (Figure 6D&E), which suggests that the HCl chitosan is the most immunogenic when 
the quantity is kept constant. The HCl has been shown to exhibit not only high adsorption efficiency, 
but also high PspA adsorbance and high immunogenicity. In contrast, the glycol exhibited the lowest 
surface marker expressions. When PspA4Pro was adsorbed to the particles, the pattern of the results 
were similar, with chitosan HCl still exhibiting high surface marker expression (data not shown), 
suggesting that PspA4Pro on the particle surface does not contribute to immunogenicity of the 
particles. The toxicity to the cells were minimal (Figure 6F), indicating that the immunogenic effects 
and processes indicated by the upregulation in CD40 and CD86 were not detrimental to the cells.
4. Discussion
PLGA and chitosan have been of interest as materials for delivery vehicles, due to biocompatibility, 
efficacy and accessibility. The potential application of the combination of PLGA and chitosan for 
vaccines, was confirmed in this study, as PLGA and chitosan polymers of different characteristics were 
evaluated for NP characteristics and immunogenicity.
4.1. Effect and differences between PLGA variations
The Initial characterisation of the PLGA NPs suggested that the polymers did not contribute to any 
significant difference in particle size or surface charge. However, the EST PLGA NPs exhibited 
significantly lower PspA4Pro adsorption compared to the other PLGAs (Figure 1). The difference in 
adsorption could be due to the greater surface hydrophobicity stemming from the ester end-group of 
the polymer. This result has been observed in other studies and appears to be equally influenced by 
the molecular properties of the protein [16]. 
In these studies, the expression of CD40 and CD86 cell surface markers, were used to determine 
immunogenicity, as they are important markers for DC activation. CD40 ligation is known to be an 
important process for maturation of DCs and contributes to subsequent activation of T cells through 
mechanisms such as the secretion of IL-12 [17]. The CD40 upregulation is also associated with CD86 
and MHC II upregulation, which are important for co-stimulation and antigen presentation, 
respectively [18]. 
Despite the lack of major differences in particle characteristics made from different PLGAs, the 
immunogenicity was consistently lower for the EST PLGA NPs. The acid terminated PLGAs with lower 
molecular weight exhibited the highest immunogenicity, suggesting that the end groups have a 
significant contribution to the interaction with DCs, without affecting characteristics such as size and 
surface charge. Surface characteristics like hydrophobicity is widely recognised to influence particle 
interaction with DCs, however the greater hydrophobic nature of esters would be predicted to 
increase cell uptake [19] and immunogenicity [20], which is contrary to the results here. It could be 
that some ester end groups undergo hydrolysis to form acid groups and thus do not exhibit the 
immunogenicity associated with hydrophobicity. The HMW PLGA NP also exhibited significantly lower 
induction of CD40 and CD86 compared to the REF and LAC PLGAs. A potential explanation could again 
be due to the lower number of end terminal groups in the HMW compared to the REF, for a given 
equal mass. This would also reinforce the importance of end terminal group as demonstrated by the 
results from the ester end terminal group.
4.2. Effect and differences between chitosan variations
Chitosan is a widely studied and recognised component of experimental vaccine formulations. 
However, as shown in the results, there are several variants which can exhibit significant differences 
in the particle size and surface charge, as well as surface adsorption of PspA4Pro. To determine the 
effects of each chitosan, the initial goal was to determine the resulting characteristics of NPs made 
from using constant coating concentrations during preparation (Section 3.3). It was apparent that each 
chitosan resulted in unique particle characteristics. An expected confirmation was that the negatively 
charged chitosans such as CMC and oligomer would not be appropriate for antigen adsorption. This 
was due to the negative charge resulting in reduced affinity for protein molecules which may be 
negatively charged at physiological pH. The chitosans were shown to contribute not only to the 
adsorption efficiency of PspA4Pro, but also to the particle characteristics, as seen with the increased 
average particle size after coating with PspA4Pro (Figure 3A). The zeta potential also changed after 
PspA4Pro coating, but there were no patterns associated with the change. HCl, LMW and TMC 
chitosans decreased in zeta potential, whereas it increased with the glutamate and glycol chitosans. 
Furthermore, the low PspA4Pro adsorption on the CMC and oligomer NPs (Figure 3E) could be 
attributed to the negative zeta potential. However, uncoated PLGA NPs exhibited high adsorption 
(Figure 1D). This suggests that the differences in PspA4Pro adsorption may not be solely dependent 
on the zeta potential, but also other molecular interactions such as hydrophobic interactions between 
PspA4Pro and the NP surface [21]. 
To examine the effects of chitosan concentration on the particle characteristics, the effect of 
preparatory concentration of chitosans was investigated. The results were used to prepare particles 
with constant amounts of adsorbed chitosan. The effects on particle characteristics and 
immunogenicity from different chitosan concentrations during preparation demonstrated unique 
patterns between chitosans (Figure 3-6). Chitosan HCl exhibited the properties which may be most 
ideal as a candidate for vaccine formulation, considering the particle characteristics, adsorption of 
chitosan and PspA, and the immunogenicity. Evaluating the immunogenic effects of chitosan coating 
on the NPs revealed that the size, PDI, and zeta potential values alone could not fully account for the 
differences in CD40 and CD86 cell surface upregulation. As the changes in particle characteristics are 
unique between each chitosan, the upregulation of the cell surface markers is likely as a result of the 
changes to both particle characteristics, as well as the intrinsic immunogenic effects of the chitosan 
polymer itself. For example, chitosan HCl generally appeared to exhibit greater upregulation of both 
CD40 and CD86 than the LMW and glutamate chitosans, despite the NPs exhibiting similar particle 
sizes and surface charge. These differences in immunogenicity could be due to differences in how each 
chitosan variation interacts with the DCs or how it induces immunogenicity, such as through the cyclic 
GMP–AMP receptor stimulator of interferon genes (cGAS-STING) signalling pathway [10]. 
In addition to the resulting particle properties, chitosan HCl may be beneficial from a production 
perspective as it is a salt. This enables solubilisation of chitosan HCl in water, as opposed to the non-
salt chitosans. The solubilisation could potentially enable coating of particles without requirement for 
acidifying the solution during that stage of preparation, and thus reduce potential for degradation of 
the particle components. Of the chitosan salt form tested, it is also interesting to note that the 
glutamate salt chitosan exhibited different immunogenic characteristics to the HCl salt. This could be 
due to the difference in salt group or the difference in the molecular weight range differences between 
the HCl (30-400 kDa) and glutamate (30-200 kDa).
This leads to the aspects of the chitosans, molecular weight and degree of deacetylation, which could 
not be fully controlled. The chitosans could be clustered into two size groups; a larger size range (30-
500 kDa) for HCl, CMC and Glycol, and a narrower size range (30-200 kDa) for LMW, TMC, Oligomer 
and glutamate. There is also further potential for differences in polymer size distribution within these 
size ranges, which many affect the interaction. Although the degree of acetylation for the tested 
chitosans were all >75%, it is also unclear how much influence the remaining 25% would have for each 
chitosan. Existing literature indicates that both high and low molecular weight chitosan can exhibit 
immunogenicity and could be intertwined with the degree of acetylation [22, 23]. Despite these 
uncertainties, chitosan HCl exhibits not only low particle size change upon coating and high 
immunogenicity, but also greater versatility during NP preparation due to the enhanced solubility 
offered by the salt form.
4.3. Outlook of the PspA4Pro adsorbed, chitosan coated, PLGA NP as a vaccine against S. pneumoniae
In addition to NP characteristics and adjuvant properties, an effective vaccine formulation must 
contain an appropriate antigen which can provide the immune system with a suitable target. In this 
experiment, PspA4Pro, which is a recombinant protein found on the surface of S. pneumoniae, was 
incorporated on the surface of the NPs. The protein offers potentially greater protective coverage 
between different S. pneumoniae serotypes, compared to commercially available conjugate 
pneumococcal vaccines [24]. The immunogenic properties of PspA4Pro are also advantageous 
compared to polysaccharide antigen that are T cell independent and induce poor memory responses 
[24]. In the current study, the incorporation of the PspA4Pro to the surface of the particles could be 
formed through the formation of electrostatic and hydrophobic interaction with the surface of the 
PLGA NP. This preparation method exhibited high adsorption efficiency (Figure 3E) and could be useful 
for the delivery to the immune cells of the lung, in combination with the immunogenic properties of 
the chitosan HCl coated PLGA NPs shown through the upregulation of the CD40 and CD86 on the DCs 
(Figure 6D&E). Considering the pathology of S. pneumoniae infection, inhalation of NPs into the lungs 
would be a suitable avenue of delivery, as it mimics the natural pathology of the bacteria. Although 
PspA4Pro is expected to cover most pneumococcal strains, there have been evidence to indicate that 
PspA4Pro alone is insufficient for coverage of all serotypes. PspA4Pro generated serum IgG with 
binding to bacteria with expression of PspA from clades 3, 4 and 5 (family 2), but no binding to bacteria 
expressing PspA from clades 1 and 2 (family 1) [25]. Further investigation is ongoing to incorporate 
another pneumococcal protein which could resolve this potential issue.
4.4. Future direction of in vitro assays in analysing NP impact within the lung environment
In order to further elucidate translatability of the results to the larger, overall immune response, there 
are several aspects which could be investigated in the future. These would include investigating the 
effect of NP uptake by macrophages, which can account for a high degree of leukocytes present in 
areas such as the lungs, exhibit high phagocytic capacity, and are known to take up particles of a wide 
range of sizes and forms [26]. They have also been shown to have a role in the modulation of cytokines 
and T cells, affecting subsequent responses such as mucous production and inflammatory cytokines 
[27]. In addition, epithelial cells of the mucosal linings are also known to take part in antigen 
presentation through surface expression of MHC II and subsequent presentation [28], thus it would 
be beneficial to understand the significance of contribution of these other entities. In terms of the DC 
response, establishing the correlation of the CD40 and CD86 upregulation to the antigen specific 
antibody production and T cell response would offer a valuable means for evaluating and optimising 
formulations in vitro, in an ethical acceptable manner. By optimising the uptake and interaction of the 
formulation with the cells present in the environment to induce the desired processes, there is 
potential for even greater protective effects, allowing for lower dosages and thus potentially reduced 
booster does, as well as cheaper production. 
5. Conclusion
NPs made from ester-ended PLGA polymers exhibited significantly lower immunogenicity in JAWSII 
cells compared to acid-ended PLGA NPs, which could correspond to the difference in surface charge. 
Upon coating the NP with chitosan, NPs coated with negatively charged chitosans generally exhibited 
lower immunogenicity compared to NPs coated with positively charged chitosan. The adsorbance of 
chitosan varied and upon coating with consistent loading, the NP coated with chitosan HCl (30-400 
kDa Mw), induced high immunogenicity, through CD40 and CD86 expression on JAWSII DCs.
Acknowledgements
This work was supported by the Medical Research Council [grant number MR/P022758/1]
References
1. Demento, S.L., et al., Role of sustained antigen release from nanoparticle vaccines in shaping 
the T cell memory phenotype. Biomaterials, 2012. 33(19): p. 4957-4964.
2. Irvine, D.J., et al., Synthetic Nanoparticles for Vaccines and Immunotherapy. Chemical 
Reviews, 2015. 115(19): p. 11109-46.
3. Pati, R., M. Shevtsov, and A. Sonawane, Nanoparticle Vaccines Against Infectious Diseases. 
Frontiers in immunology, 2018. 9: p. 2224-2224.
4. Silva, A.L., et al., PLGA particulate delivery systems for subunit vaccines: Linking particle 
properties to immunogenicity. Human vaccines & immunotherapeutics, 2016. 12(4): p. 1056-
1069.
5. Jain, S., R.K. Sharma, and S.P. Vyas, Chitosan nanoparticles encapsulated vesicular systems 
for oral immunization: preparation, in-vitro and in-vivo characterization. Journal of Pharmacy 
and Pharmacology, 2006. 58(3): p. 303-310.
6. Allahyari, M., et al., In-vitro and in-vivo comparison of rSAG1-loaded PLGA prepared by 
encapsulation and adsorption methods as an efficient vaccine against Toxoplasma gondii”. 
Journal of Drug Delivery Science and Technology, 2020. 55: p. 101327.
7. Chesko, J., et al., An Investigation of the Factors Controlling the Adsorption of Protein 
Antigens to Anionic PLG Microparticles. Journal of Pharmaceutical Sciences, 2005. 94(11): p. 
2510-2519.
8. Pawar, D., et al., Development and characterization of surface modified PLGA nanoparticles 
for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune 
adjuvant activity. European Journal of Pharmaceutics and Biopharmaceutics, 2013. 85(3, 
Part A): p. 550-559.
9. Wang, Z.-B., et al., The mechanism of action of acid-soluble chitosan as an adjuvant in the 
formulation of nasally administered vaccine against HBV. RSC Advances, 2016. 6(99): p. 
96785-96797.
10. Carroll, E.C., et al., The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA 
Sensor cGAS-STING-Dependent Induction of Type I Interferons. Immunity, 2016. 44(3): p. 597-
608.
11. Xing, L., et al., Chemical Modification of Chitosan for Efficient Vaccine Delivery. Molecules 
(Basel, Switzerland), 2018. 23(2): p. 229.
12. Jia, J., et al., Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of 
Cancer Immunotherapy. Frontiers in Oncology, 2018. 8(404).
13. Benson, R.A., et al., Antigen presentation kinetics control T cell/dendritic cell interactions and 
follicular helper T cell generation in vivo. Elife, 2015. 4.
14. Chang, T.Z., et al., Effects of ovalbumin protein nanoparticle vaccine size and coating on 
dendritic cell processing. Biomaterials science, 2017. 5(2): p. 223-233.
15. Kunda, N.K., et al., Pulmonary dry powder vaccine of pneumococcal antigen loaded 
nanoparticles. International Journal of Pharmaceutics, 2015. 495(2): p. 903-912.
16. Gessner, A., et al., Influence of surface charge density on protein adsorption on polymeric 
nanoparticles: analysis by two-dimensional electrophoresis. European Journal of 
Pharmaceutics and Biopharmaceutics, 2002. 54(2): p. 165-70.
17. Gerlach, A.-M., et al., Role of CD40 ligation in dendritic cell semimaturation. BMC 
immunology, 2012. 13: p. 22-22.
18. Villadangos, J.A., et al., MHC Class II Expression Is Regulated in Dendritic Cells Independently 
of Invariant Chain Degradation. Immunity, 2001. 14(6): p. 739-749.
19. Liu, Y., et al., Effects of engineered nanoparticles on the innate immune system. Seminars in 
Immunology, 2017. 34: p. 25-32.
20. Moyano, D.F., et al., Nanoparticle Hydrophobicity Dictates Immune Response. Journal of the 
American Chemical Society, 2012. 134(9): p. 3965-3967.
21. Yu, Q., et al., Regulating Protein Corona Formation and Dynamic Protein Exchange by 
Controlling Nanoparticle Hydrophobicity. Frontiers in bioengineering and biotechnology, 
2020. 8: p. 210-210.
22. Markushin, S.G., et al., Effect of Molecular Weight and Degree of Acetylation on Adjuvantive 
Properties of Chitosan Derivatives. Applied Biochemistry and Microbiology, 2018. 54(5): p. 
512-517.
23. Al-Nemrawi, N.K., A.R. Okour, and R.H. Dave, Surface modification of PLGA nanoparticles 
using chitosan: Effect of molecular weight, concentration, and degree of deacetylation. 
Advances in Polymer Technology, 2018. 37(8): p. 3066-3075.
24. da Silva, M.A., et al., Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae 
Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. 
Clinical and Vaccine Immunology, 2017. 24(8): p. e00118-17.
25. Rodrigues, T.C., et al., Mucosal immunization with PspA (Pneumococcal surface protein A)-
adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. 
PLoS One, 2018. 13(1): p. e0191692.
26. Hardy, C.L., et al., Differential uptake of nanoparticles and microparticles by pulmonary APC 
subsets induces discrete immunological imprints. Journal of Immunology, 2013. 191(10): p. 
5278-90.
27. Blank, F., et al., Interaction of biomedical nanoparticles with the pulmonary immune system. 
Journal of Nanobiotechnology, 2017. 15(1): p. 6.
28. Wosen, J.E., et al., Epithelial MHC Class II Expression and Its Role in Antigen Presentation in 
the Gastrointestinal and Respiratory Tracts. Frontiers in Immunology, 2018. 9(2144).
Figure Captions
Figure 1. Particle characteristics of NPs prepared from REF, EST, HMW and LAC PLGA polymers. The 
particle size (A), PDI (B), and zeta potential (C) with and without PspA4Pro adsorption. The adsorption 
efficiency of PspA4Pro to PLGA NPs (D). (n=3 independently prepared batches, mean±SD, significantly 
higher adsorption efficiency of a group over another is indicated by the respective letter, p<0.05).
Figure 2. Toxicity of PLGA NPs (A), upregulation of CD40 (B) and CD86 (C) surface markers after 
incubation for 24 h (n=4, representative of 3 independent experiments with independent batches of 
NP, mean±SD. Significantly higher surface marker expression between the groups is indicated by the 
respective letter, p<0.05).
Figure 3. The size (A), PDI (B) and zeta potential (C) of PLGA NP coated with chitosans and PspA4Pro, 
and the adsorption efficiency of chitosans on PLGA NPs (D) and PspA4Pro on chitosan coated PLGA 
NPs (E) (n=3 independent batches, mean±SD). Upregulation of CD40 (F) and CD86 (G) surface markers 
after incubation with PLGA NPs for 24 h (n=4, representative of 3 independent experiments with 
independent batches of NP, mean±SD) (significantly higher difference compared to another group is 
indicated by the respective letter, p<0.05).
Figure 4. The particle size (A), PDI (B), and zeta potential (C) of PLGA NPs coated with various 
preparatory concentrations of chitosans (0.2, 0.5 1 and 2 mg/mL). The loading capacity (D) and 
adsorption efficiency (E) of the different chitosan at 0.2, 0.5, 1 and 2 mg/mL chitosan concentrations 
during preparation (n=3 independent batches, mean±SD, a statistically significant correlation 
according to linear regression between the preparatory concentration and response is indicated by 
the * above the group, p<0.05).
Figure 5. CD40 (black) and CD86 (grey) surface upregulation on JAWSII cells after incubation with PLGA 
NPs coated with varying preparatory chitosan concentrations (0, 0.2, 0.5 1.0 and 2.0 mg/mL) and 
derivatives, HCl (A), LMW (B), TMC (C), Glutamate (D) and Glycol (E). (n=4, representative of 3 
independent experiments with independent batches of NP, mean±SD).
Figure 6. The particle size (A), PDI (B) and zeta potential (C) of PLGA NPs coated with constant loading 
capacity of HCl, LMW, TMC Glutamate and Glycol (n=3 independent batches, mean±SD). Upregulation 
of CD40 (D) and CD86 (E) surface markers and cell viability (F) after incubation with PLGA NPs coated 
with chitosans for 24 h (n=4, representative of 3 independent experiments with independent batches 









Table 1. PLGA polymers with differing lactic acid:glycolic acid ratio, terminal group and molecular 
weight.
Polymer L:G ratio Terminal group Average Mw (kDa)
REF 50:50 Acid 7-17
EST 50:50 Ester 7-17
HMW 50:50 Acid 24-38
LAC 75:25 Acid 4-15
reference (REF), ester terminal group (EST), high-molecular weight (HMW) and carboxylic acid end group (LAC) 
Table 2. Different derivatives of chitosan 
Chitosan name Molecular weight Degree of deacetylation Product #
HCl 30-400 kDa 80-95% 43001 HMC
Low molecular weight (LMW) 50-190 kDa 75-85% 448869 Aldrich
Trimethylchitosan (TMC) 50-190 kDa NA Prepared from LMW
Carboxymethylchitosan (CMC) 30-500 kDa 80-95% 43002 HMC
Oligomer <5 kDa ≥75% 44009 HMC
Glutamate 30-200 kDa NA 44006 HMC
Glycol 400 kDa NA G7753 Sigma
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